ArticleBreast cancer (Tokyo, Japan)2026
Triggering receptors expressed on myeloid cells (TREM-1) and TREM-2 as predictors of pathological complete response to neoadjuvant therapy in triple-negative breast cancer.
Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTriple-negative breast cancer (TNBC) is one of the most aggressive subtypes of breast cancer, characterized by early metastasis, high recurrence rates, and limited targeted therapy options. Pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT) is a well-established prognostic surrogate for long-term outcome, yet reliable predictive biomarkers remain elusive. TREM-1 and TREM-2 are key immune modulators that shape the balance between proinflammatory and immunosuppressive signaling within the tumor microenvironment (TME). This study aimed to evaluate the predictive utility of TREM-1 and TREM-2 expression for pCR in TNBC after NACT.
methodsPre-treatment biopsies from 71 patients with early or locally advanced TNBC treated with chemotherapy-based NACT were analyzed by immunohistochemistry (IHC) for TREM-1 and TREM-2. Stromal/TIL H-scores were used for the final analysis. Clinical records were reviewed for treatment regimen. Cutoff values were determined using receiver operating characteristic (ROC) analysis based on the Youden index, and multivariable logistic regression was used to identify independent predictors of pCR.
resultsHigh stromal TREM-1 expression (> 90) independently predicted higher pCR rates (OR 12.25; p = 0.003), whereas high stromal TREM-2 expression (> 10) correlated with lower pCR likelihood (OR 0.105; p = 0.030). The predefined high Ki-67 group and lower T-stage also predicted pCR. In secondary analyses, tumor-cell TREM-1 and TREM-2 expression were not significantly associated with pCR.
conclusionThe opposing associations of stromal TREM-1 and TREM-2 with pCR suggest that the TIL-mediated tumor microenvironment may play an important role in shaping treatment sensitivity in TNBC. High TREM-1 expression is linked to an inflammatory, treatment-responsive phenotype, whereas high TREM-2 expression reflects an immunosuppressive, resistant state. Their combined evaluation may provide clinically meaningful insights for predicting therapeutic response and for developing novel immunomodulatory strategies in TNBC.
Indexed as
Identifiers
42766275What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.